跳至主要内容
临床试验/CTRI/2020/10/028188
CTRI/2020/10/028188尚未招募2 期

Role of Parecoxib, A Selective Cyclooxygenase-2 Inhibitor, for Reduction of Severity of Acute Pancreatitis: A Randomized Controlled Trial

Dr Pramod Kumar Garg0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Acute pancreatitis as defined by revised Atlanta classification.
  • 2. The time interval from the onset of symptoms to presentation should be less than 7 days.
  • 3. Systemic inflammatory response syndrome (SIRS) persisting for more than 24 hours.

排除标准

  • 1. Age less than 18 years or more than 70 years
  • 2. Patients with Grade 2 or more organ failure as per Modified Marshallâ??s criteria.
  • 3. Patients with a serum creatinine >1.4 mg/dl
  • 4. Active or past history of GI bleeding or peptic ulcer disease
  • 5. Patients with significant co-morbidity such as coronary artery disease, chronic kidney disease, cirrhosis, chronic obstructive airway disease, inflammatory bowel disease, and congestive heart failure or malignancy.
  • 6. Patients who have history of bronchospasm, urticaria, angioneurotic edema or other allergic reactions to COX-2 inhibitors
  • 7. Patients with evidence of chronic pancreatitis
  • 8. Pregnancy and breast feeding
  • 9. Failure to give consent

研究者

发起方
Dr Pramod Kumar Garg

相似试验